These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 2879443)

  • 1. Strategies in antihypertensive therapy: implications of the kidney.
    Hollenberg NK
    Am J Med; 1986 Dec; 81(6A):15-9. PubMed ID: 2879443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The kidney and strategies for the treatment of hypertension.
    Hollenberg NK
    Am J Med; 1984 Oct; 77(4A):60-3. PubMed ID: 6207726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasodilators, antihypertensive therapy, and the kidney.
    Hollenberg NK
    Circulation; 1987 Jun; 75(6 Pt 2):V39-42. PubMed ID: 2882875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasodilators, antihypertensive therapy and the kidney.
    Hollenberg NK
    Am J Cardiol; 1987 Dec; 60(17):57I-60I. PubMed ID: 3687806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The kidney and effective antihypertensive therapy.
    Hollenberg NK
    Am J Cardiol; 1985 Dec; 56(16):52H-55H. PubMed ID: 2866706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of antihypertensive therapy on renal function.
    Rappelli A; Baldinelli A; Zingaretti O; Espinosa E; Salvi S; Fulgheri PD
    J Hypertens Suppl; 1991 Dec; 9(3):S37-40. PubMed ID: 1686783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacological basis of antihypertensive drug therapy].
    Kolck UW; Zaugg CE; Erne P
    Praxis (Bern 1994); 2004 May; 93(20):847-56. PubMed ID: 15195836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The kidney and antihypertensive therapy.
    Hollenberg NK
    Am J Cardiol; 1987 Jan; 59(2):76A-79A. PubMed ID: 2880492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model.
    Hallow KM; Lo A; Beh J; Rodrigo M; Ermakov S; Friedman S; de Leon H; Sarkar A; Xiong Y; Sarangapani R; Schmidt H; Webb R; Kondic AG
    Am J Physiol Regul Integr Comp Physiol; 2014 May; 306(9):R647-62. PubMed ID: 24500431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelin-1-induced vasopressor responses in essential hypertension.
    Kaasjager KA; Koomans HA; Rabelink TJ
    Hypertension; 1997 Jul; 30(1 Pt 1):15-21. PubMed ID: 9231815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal and hemodynamic effects of non-diuretic antihypertensive therapy.
    Batlle DC; Libre J
    Semin Nephrol; 1986 Sep; 6(3):224-40. PubMed ID: 2885908
    [No Abstract]   [Full Text] [Related]  

  • 13. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR
    Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephroprotection by antihypertensive agents.
    Schmieder RE
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S55-64. PubMed ID: 7898095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of the clinical management of hypertension. Emerging role of "specific" vasodilators as initial therapy.
    Dzau VJ
    Am J Med; 1987 Jan; 82(1A):36-43. PubMed ID: 2879462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Does the diuretic effect of calcium inhibitors play an important role in the hypertensive efficacy?].
    Maldonado Martin A; Gil Extremera B; Rubio Luengo MA
    Presse Med; 1995 Apr; 24(14):686-90. PubMed ID: 7770417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin receptor blockers for management of hypertension.
    Catanzaro DF; Frishman WH
    South Med J; 2010 Jul; 103(7):669-73. PubMed ID: 20531060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium channel blockers versus angiotensin-converting enzyme inhibitors: renal effects.
    Linas S
    Am J Kidney Dis; 1990 Oct; 16(4 Suppl 1):15-9. PubMed ID: 2220796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and trends in the drug treatment of essential hypertension.
    van Zwieten PA
    J Hypertens Suppl; 1992 Dec; 10(7):S1-12. PubMed ID: 1363322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.